Literature DB >> 28315646

Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate Corynebacterium bovis.

Christopher A Manuel1, Stacey M Bagby2, Julie A Reisinger2, Umarani Pugazhenthi3, Todd M Pitts4, Stephen B Keysar4, John J Arcaroli4, Jori K Leszczynski5.   

Abstract

Human patient-derived xenograft (PDX) tumors, propagated in immunodeficient mice, are rapidly growing in use as a model for cancer research. Horizontal transfer between mice, without in vitro cell culture, allows these tumors to retain many of their unique characteristics from their individual patient of origin. However, the immunodeficient mouse strains used to grow these tumors are susceptible to numerous opportunistic pathogens, including Corynebacterium bovis. At our institution, 2 in vivo tumor banks of PDX tumors had been maintained within nude mouse colonies enzootically infected with C. bovis. Elimination of C. bovis from these colonies required the aseptic harvest and horizontal transfer of tumor tissue between infected and naïve recipient mice without cross-contamination. Out of necessity, we developed a standard operating procedure using enhancements to traditional aseptic surgical technique with concurrent application of both procedural and physical barriers to prevent C. bovis transmission. By using these methods, all 61 unique PDX tumor models were successfully harvested from C. bovis-infected mice and transferred into recipient mice without transmission of infection. Our data demonstrate that, in situations where C. bovis-free colonies can be established and maintained, this procedure can successfully be used to eliminate C. bovis from an in vivo tumor bank of valuable PDX tumors.

Entities:  

Mesh:

Year:  2017        PMID: 28315646      PMCID: PMC5361042     

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  30 in total

1.  Evaluation of the antimicrobial properties of an alcohol-free 2% chlorhexidine gluconate solution.

Authors:  Barbara DeBaun
Journal:  AORN J       Date:  2008-05       Impact factor: 0.676

2.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick
Journal:  Nat Protoc       Date:  2009-10-29       Impact factor: 13.491

3.  Strategies to prevent, treat, and provoke Corynebacterium-associated hyperkeratosis in athymic nude mice.

Authors:  Holly N Burr; Neil S Lipman; Julie R White; Junting Zheng; Felix R Wolf
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-05       Impact factor: 1.232

4.  Outbreaks of hyperkeratotic dermatitis of athymic nude mice in northern Italy.

Authors:  E Scanziani; A Gobbi; L Crippa; A M Giusti; R Giavazzi; E Cavalletti; M Luini
Journal:  Lab Anim       Date:  1997-07       Impact factor: 2.471

Review 5.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Authors:  Ketao Jin; Lisong Teng; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

6.  Comparative of a new and innovative 2% chlorhexidine gluconate-impregnated cloth with 4% chlorhexidine gluconate as topical antiseptic for preparation of the skin prior to surgery.

Authors:  Charles E Edmiston; Gary R Seabrook; Christopher P Johnson; Daryl S Paulson; Christopher M Beausoleil
Journal:  Am J Infect Control       Date:  2007-03       Impact factor: 2.918

7.  A clinical study comparing the skin antisepsis and safety of ChloraPrep, 70% isopropyl alcohol, and 2% aqueous chlorhexidine.

Authors:  John S Hibbard; Gayle K Mulberry; Ann R Brady
Journal:  J Infus Nurs       Date:  2002 Jul-Aug

Review 8.  Patient-derived tumor xenografts: transforming clinical samples into mouse models.

Authors:  Despina Siolas; Gregory J Hannon
Journal:  Cancer Res       Date:  2013-06-03       Impact factor: 12.701

9.  Pathogenicity and genetic variation of 3 strains of Corynebacterium bovis in immunodeficient mice.

Authors:  Vandana S Dole; Kenneth S Henderson; Richard D Fister; Michael T Pietrowski; Geomaris Maldonado; Charles B Clifford
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-07       Impact factor: 1.232

Review 10.  The forgotten role of alcohol: a systematic review and meta-analysis of the clinical efficacy and perceived role of chlorhexidine in skin antisepsis.

Authors:  Matthias Maiwald; Edwin S Y Chan
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more
  7 in total

1.  Detection and Elimination of Corynebacterium bovis from Barrier Rooms by Using an Environmental Sampling Surveillance Program.

Authors:  Christopher A Manuel; Umarani Pugazhenthi; Shannon P Spiegel; Jori K Leszczynski
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

2.  Effects of Corynebacterium bovis on Engraftment of Patient-derived Chronic-Myelomonocytic Leukemia Cells in NSGS Mice.

Authors:  Alexis R Vedder; Emily L Miedel; Natalie H Ragland; Maria E Balasis; Christopher T Letson; Robert W Engelman; Eric Padron
Journal:  Comp Med       Date:  2019-07-26       Impact factor: 0.982

3.  Effect of Antimicrobial Prophylaxis on Corynebacterium bovis Infection and the Skin Microbiome of Immunodeficient Mice.

Authors:  Christopher A Manuel; Linda K Johnson; Uma Pugazhenthi; Derek L Fong; Michaelk Fink; Lauren M Habenicht; Jori K Leszczynski; I R Diana; Michael J Schurr; Daniel N Frank
Journal:  Comp Med       Date:  2022-04-04       Impact factor: 1.565

4.  Pathology Principles and Practices for Analysis of Animal Models.

Authors:  Sue E Knoblaugh; Tobias M Hohl; Krista M D La Perle
Journal:  ILAR J       Date:  2018-12-01

5.  Facility-wide Eradication of Corynebacterium bovis by using PCR-validated Vaporized Hydrogen Peroxide.

Authors:  Emily L Miedel; Natalie H Ragland; Robert W Engelman
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-07-13       Impact factor: 1.232

Review 6.  Melanoma models for the next generation of therapies.

Authors:  E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino
Journal:  Cancer Cell       Date:  2021-02-04       Impact factor: 31.743

7.  A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.

Authors:  Katrin P Guillen; Maihi Fujita; Andrew J Butterfield; Sandra D Scherer; Matthew H Bailey; Zhengtao Chu; Yoko S DeRose; Ling Zhao; Emilio Cortes-Sanchez; Chieh-Hsiang Yang; Jennifer Toner; Guoying Wang; Yi Qiao; Xiaomeng Huang; Jeffery A Greenland; Jeffery M Vahrenkamp; David H Lum; Rachel E Factor; Edward W Nelson; Cindy B Matsen; Jane M Poretta; Regina Rosenthal; Anna C Beck; Saundra S Buys; Christos Vaklavas; John H Ward; Randy L Jensen; Kevin B Jones; Zheqi Li; Steffi Oesterreich; Lacey E Dobrolecki; Satya S Pathi; Xing Yi Woo; Kristofer C Berrett; Mark E Wadsworth; Jeffrey H Chuang; Michael T Lewis; Gabor T Marth; Jason Gertz; Katherine E Varley; Bryan E Welm; Alana L Welm
Journal:  Nat Cancer       Date:  2022-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.